Cost-effectiveness of empegfilgrastim (Extimia®) for the prevention of severe neutropenia in patients with malignant neoplasm of female breast
Granulocyte colony stimulating factor (G-CSF), particularly filgrastim, significantly reduces the chance of developing side effects of chemotherapy. Pegylated G-CSF products are characterized as longer-acting drugs in comparison with non-pegylated forms. The aim of the study was to assess the cost-e...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
IP Habib O.N.
2016-06-01
|
| Series: | Современная онкология |
| Subjects: | |
| Online Access: | https://modernonco.orscience.ru/1815-1434/article/viewFile/27077/pdf |